BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Therapeutic insights at BIO‑Europe 2026

Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website

58 organizations at BIO-Europe 2026 present work in therapeutic insights: 34 drug developers, 15 investors, 5 service providers and 4 academic, government and non-profit bodies. Between them they bring 92 presentations to the program. Most represented: Merck KGaA (11 on the program), Boehringer Ingelheim (5 on the program), Informa (4 on the program). As of Nov 10, 2026.

All 473 organizations at BIO-Europe 2026 →

Format
Top represented
Showing 1–10 of 58 organizations
OrganizationBIO-Europe 2026 Attendance
Merck KGaA
Darmstadt, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Science and technology company active in healthcare, life science and electronics; operates as EMD Serono and MilliporeSigma in North America.
Talk
Mon Nov 9
09:00–10:00
Building Your BD Career: What Really Moves the Needle
What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts.
with BD&L Peers Community, Thuja Capital, Tubulis +1 more
Talk
Mon Nov 9
15:00–16:15
Merck's EMEA Advance Biotech Grant Program
Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market.
with Stemmatters, M Ventures, ConvEyXO +4 more
Panel
Mon Nov 9
13:00–13:45
Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem
How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery.
with MichBio, XGEN Venture, Boehringer Ingelheim
Panel
Tue Nov 10
14:00–14:45
Immunology under the microscope: New frontiers
What is new in drugs for autoimmune and inflammatory diseases: emerging targets, recent trial results, and where companies are investing and partnering.
with MRM Health, Hansa Biopharma, Claris Ventures
Talk
Tue Nov 10
09:15–09:30
Pharma Presentation: Merck
Merck's three businesses: medicines for diseases such as multiple sclerosis and cancer, tools for scientists, and technology for electronics.
Panel
Tue Nov 10
16:00–16:45
Unlocking Clinical Trial Systems
How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely.
with R Kupiec Consulting, Parexel, AstraZeneca
Panel
Wed Nov 11
09:00–09:45
From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling
How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance.
with FRESCI, TissUse, European Commission +2 more
Boehringer Ingelheim
Ingelheim am Rhein, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Family-owned pharmaceutical company developing human and animal health medicines.
Panel
Mon Nov 9
13:00–13:45
Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem
How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery.
with MichBio, XGEN Venture, Merck KGaA
Talk
Tue Nov 10
13:00–14:00
Biologics Manufacturing Excellence
How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently.
with Immatics, ValiRx, Pfizer +1 more
Talk
Tue Nov 10
09:30–09:45
Pharma Presentation: Boehringer Ingelheim
Boehringer Ingelheim, independent since 1885, and its research on human and animal medicines for diseases that lack good treatments.
Panel
Wed Nov 11
10:00–10:45
Envisioning the future of ophthalmology
What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise.
with Micro CRISPR, AAVantgarde Bio, Inveready +1 more
Panel
Wed Nov 11
10:00–10:45
Most Favoured Nations: A Game-Changer for Biotech Dealmaker?
How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans.
with EUCOPE, Bristol Myers Squibb
Informa
London, United Kingdom
Consulting, legal & services
Events, publishing and data group that runs BIO-Europe and publishes BioXconomy.
Keynote
Mon Nov 9
10:15–10:30
Opening Remarks
The Big Picture Plenary Series · with Ministry of Economic Affairs, Industry, Climate Action and Energy of North Rhine-Westphalia, Biotechnology Innovation Organization (BIO)
Talk
Mon Nov 9
09:30–10:00
partneringONE essentials workshop
Newcomers learn what to expect from partnering meetings, including timing and etiquette, and how to get the most from the partneringONE system.
Panel
Tue Nov 10
09:00–09:45
Networks or neurons: What’s next in CNS dealmaking?
What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop.
with Servier, Biovance Capital, Otsuka +2 more
Talk
Tue Nov 10
11:30–12:00
partneringONE power up workshop
Experienced delegates learn advanced partneringONE features and team habits that save time and raise how often their meeting requests are accepted.
Panel
Wed Nov 11
13:00–13:45
BIO-Europe Media Round-Up: The Stories Shaping Biopharma Right Now
Journalists pick out the biggest biopharma news stories and deal trends of the moment and explain what they mean for dealmakers.
with BioWorld
Panel
Wed Nov 11
09:00–09:45
How is the APAC region reshaping global biopharma?
How China, Japan, South Korea and other Asia-Pacific countries are moving from making drugs to inventing them, and how Western firms can partner.
with MSD, Sinovoy Health Group, WinHealth Pharma +1 more
Johnson & Johnson
New Brunswick, NJ
◆Platinum Sponsor · Johnson & Johnson Innovation
Large pharmaPlatinum sponsor
Healthcare company developing innovative medicines and medical technologies; its Innovation unit partners with external researchers and start-ups.
Panel
Mon Nov 9
16:15–17:00
Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work?
What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies.
with 59 North Communications, Gateway Factory, CSL Behring +1 more
Panel
Tue Nov 10
10:00–10:25
Regulatory Updates for Orphan and Pediatric Medicines
How updated EU drug laws change the rewards for rare-disease and children's medicines, such as longer protection from competing copies.
Panel
Wed Nov 11
10:00–10:45
Envisioning the future of ophthalmology
What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise.
with Micro CRISPR, Boehringer Ingelheim, AAVantgarde Bio +1 more
Panel
Wed Nov 11
12:00–12:45
What's Next for Biomanufacturing Strategies?
Where the manufacturing of biological medicines is heading, from sturdier supply chains and industry mergers to AI and new ways to scale up.
with Resolution Therapeutics, Valneva, IDT Biologika
Novo Nordisk
Bagsværd, Denmark
◆Gold Sponsor
Large pharmaGold sponsor
Danish pharmaceutical company, branded Novo since September 2026, making medicines for diabetes, obesity and rare diseases.
Panel
Mon Nov 9
11:15–12:00
Unlocking Pharma’s Productivity Potential
Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive.
with Norstella, M Ventures, Blackstone Life Sciences +1 more
Business of Biotech
Panel
Tue Nov 10
15:30–15:55
Accelerating Innovation: Creating the Right Environment for Success in Biopharma Partnerships
How to design partnerships that work, from payments tied to research milestones and shared risk to guarding intellectual property while sharing ideas.
Panel
Tue Nov 10
10:00–10:45
Cardiometabolic innovations beyond GLP-1 – Where are we now?
Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going.
with LifeArc, Atrogi, IsomAb +2 more
Panel
Tue Nov 10
15:00–15:45
Longevity – Are we getting younger?
What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape.
with Longevity.Technology, Asabys Partners, Chrysea +1 more
Sofinnova Partners
Paris, France
Investors & finance
Life sciences venture capital firm investing from seed to late stage in biotech, medtech and industrial biotech.
Panel
Mon Nov 9
16:00–16:45
Cell and Gene Therapy: What Should You Know?
Where gene therapies stand across diseases, and what shifting funding and partnerships mean for regulation, manufacturing, investment and market access.
with BioM, VeonGen Therapeutics
Panel
Mon Nov 9
16:00–16:45
Fuelling Innovation: The State of Early-Stage Investment in Biotech
Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting.
with European Innovation Council, Eir Ventures, High-Tech Gründerfonds +2 more
Panel
Tue Nov 10
15:00–15:45
Scaling Success: The Dynamics of Late-Stage Investment in Biotech
How investors back biotechs whose products are close to market, from regulatory hurdles and scaling up to going public or being acquired.
with Camarco, BNP Paribas Asset Management, TVM Capital Life Science +2 more
Eli Lilly
Indianapolis, IN
◇Silver Sponsor
Large pharmaSilver sponsor
Global pharmaceutical company with medicines in diabetes, obesity, oncology, immunology and neuroscience.
Keynote
Tue Nov 10
13:00–13:45
Keynote: Day in the Life of an experienced dealmaker
Experienced drug-company dealmakers and venture investors share how they see the life sciences industry today and how biotechs can find their way.
with EVOLUTION Life Science Partners, ESC Advisors, Pfizer
Panel
Tue Nov 10
12:20–13:00
Women’s Health at an Inflection Point: Redefining Treatment, Regulatory Pathways and Access
How women's health care is changing, from non-hormonal and disease-modifying drugs to new approval and payment routes and new ways of naming diseases.
with McKinsey & Company, OvartiX, Apikal Therapeutics +1 more
Therapeutic InsightsRegulatory Strategy
Panel
Tue Nov 10
11:15–12:15
Women’s Health: Healthcare’s Largest Underserved Market and Biggest Growth Opportunity
Why women's health is a large, neglected market, and how much value is lost when medicine is designed around the wrong default patient.
with Eir Accelerator, European Investment Bank, Women's Health Fund +2 more
Therapeutic InsightsBusiness of Biotech
Ipsen
Boulogne-Billancourt, France
◆Platinum Sponsor
Large pharmaPlatinum sponsor
French global biopharmaceutical company focused on oncology, rare diseases and neuroscience.
Panel
Mon Nov 9
13:00–14:00
Navigating partnering and business development in a shifting global landscape
How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples.
with Syneos Health, Biogen, Genmab +2 more
Panel
Mon Nov 9
13:00–13:45
The therapeutic landscape backed by analyst insights
Which disease areas analysts rate most promising for new drugs and investment, and how new science and rule changes are reshaping them.
with Thuja Capital, Medicxi, AlphaSense
Almirall
Barcelona, Spain
◆Gold Sponsor
Large pharmaGold sponsor
Pharmaceutical company developing and marketing medicines for skin diseases, including psoriasis and atopic dermatitis.
Talk
Tue Nov 10
10:00–10:15
Pharma Presentation: Almirall
How Almirall, a Barcelona drugmaker focused on skin diseases such as psoriasis and acne, seeks partners from early research to late-stage trials.
Panel
Wed Nov 11
11:00–11:45
Beyond the surface: The rise and future of dermatology
Why skin medicine is drawing investment, from biologics for inflammatory and rare skin diseases to cosmetic treatments, and which deals are emerging.
with Kurma Partners, Dermagnostix
Debiopharm
Lausanne, Switzerland
◆Gold Sponsor
Large pharmaGold sponsor
Swiss privately owned biopharmaceutical group developing oncology and bacterial infection treatments.
Panel
Mon Nov 9
15:00–15:45
The next oncology winners: Where investors, pharma and biotech are placing their bets
Which cancer treatments, from radioactive targeted drugs to newer immunotherapies, now draw investors, and what makes a cancer biotech worth funding.
with Pullan Consulting, SRTD Biotech, Women in Life Science Denmark +1 more
Talk
Tue Nov 10
10:15–10:30
Pharma Presentation: Debiopharm International SA
How Debiopharm licenses in promising drugs for cancer and bacterial infections, tests them in trials, then picks large drug companies to sell them.

Explore the full BIO-Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Cologne. Leave your work email and we’ll be in touch.

Privacy

Download the full BIO-Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in therapeutic insights

Tell us what you sell and we’ll find the people at organizations working on therapeutic insights most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse BIO-Europe 2026 by

Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction